11.2 Medications for Alcohol and Tobacco Use Disorders

11.2 Medications for Alcohol and Tobacco Use Disorders

---

Neurobiology of Alcohol Use Disorder and the Rationale for MAUD

Alcohol (ethanol) is a central nervous system depressant that exerts complex, diffuse effects across multiple neurotransmitter networks. Its primary neurochemical mechanisms involve:

1. GABAergic Potentiation: Alcohol binds to gamma-aminobutyric acid type A ($GABA_A$) receptor complexes, enhancing the inhibitory effects of GABA. This produces sedation, muscle relaxation, anxiolysis, and cognitive slowing.
2. Glutamatergic Inhibition: Alcohol acts as an antagonist at N-methyl-D-aspartate (NMDA) glutamate receptors, suppressing the brain's primary excitatory neurotransmitter and impairing memory consolidation and motor coordination.
3. Dopaminergic and Endorphin Release: Alcohol stimulates the release of endogenous beta-endorphins, which bind to mu-opioid receptors and trigger dopamine release in the nucleus accumbens, reinforcing the desire to drink.

┌────────────────────────────────────────────────────────────────────────────────────────┐
│                     ALCOHOL NEUROCHEMICAL BALANCE AND WITHDRAWAL                       │
├────────────────────────────┬─────────────────────────────┬─────────────────────────────┤
│ Homeostatic Baseline       │ Chronic Alcohol Exposure    │ Abrupt Cessation            │
│ • Balanced GABA inhibition │ • GABA receptors down-reg.  │ • Profound GABA deficiency  │
│ • Balanced NMDA excitation │ • NMDA receptors up-reg.    │ • Massive Glutamate surge   │
│ • Normal baseline tone     │ • Tolerance developed       │ • Seizures, DTs, Dysphoria  │
└────────────────────────────┴─────────────────────────────┴─────────────────────────────┘

Chronic Adaptation and Protracted Withdrawal (PAWS)

With chronic heavy consumption, the central nervous system attempts to maintain homeostasis: it downregulates inhibitory GABA receptors and upregulates excitatory NMDA receptors. When alcohol is abruptly discontinued, the inhibitory brakes are removed while the hyperactive excitatory accelerator surges unchecked. This produces acute withdrawal: tremors, diaphoresis, tachycardia, hypertension, hallucinations, withdrawal seizures, and potentially fatal delirium tremens (DTs) (which requires acute medical detoxification with benzodiazepines).

Even after acute physical withdrawal resolves, neurochemical equilibrium does not instantly return. For weeks or months, individuals endure protracted withdrawal (Post-Acute Withdrawal Syndrome, or PAWS), characterized by hyper-glutamatergic tone, autonomic instability, insomnia, generalized anxiety, emotional blunting, and intense cravings. MAUD agents are specifically engineered to mitigate these chronic imbalances, significantly improving long-term recovery outcomes.

---

The Three FDA-Approved Medications for Alcohol Use Disorder (MAUD)

1. Acamprosate (Campral)

Pharmacological Mechanism: Acamprosate is a synthetic compound chemically similar to the endogenous amino acid taurine and GABA. It acts as a modulator of NMDA receptors and normalizes hyperactive glutamatergic neurotransmission while restoring GABAergic tone. In simple terms, acamprosate acts as a neurochemical stabilizer, quieting the "brain chatter," chronic restlessness, and post-acute cravings experienced by individuals in early alcohol recovery.

• Primary Indication: Acamprosate is indicated for the maintenance of abstinence in individuals with alcohol dependence who are already abstinent at treatment initiation. It is not effective for acute alcohol detoxification and does not treat acute withdrawal seizures or delirium tremens.
• Organ Clearance & Hepatic Safety:
  • Acamprosate is excreted entirely unchanged by the kidneys via glomerular filtration.
  • It undergoes 0% hepatic metabolism and does not interact with the cytochrome P450 enzyme system.
  • Clinical Significance: Because many individuals with long-term severe alcohol use disorder present with alcoholic hepatitis, liver cirrhosis, elevated liver transaminases (ALT/AST), or co-occurring Hepatitis C, acamprosate is the safest MAUD agent in patients with hepatic impairment.
• Contraindications and Cautions: Acamprosate is strictly contraindicated in patients with severe renal impairment (creatinine clearance $\le 30\text{ mL/min}$). A dose reduction is required in moderate renal impairment ($30-50\text{ mL/min}$).
• Pill Burden and Adherence: The standard adult dosage is two 333 mg delayed-release tablets taken three times daily (TID), totaling 1,998 mg daily (6 large tablets per day). This significant pill burden is the primary cause of poor adherence; peer specialists frequently assist peers with pill organizers, phone reminders, and mealtime pairing.

---

2. Disulfiram (Antabuse)

Pharmacological Mechanism: Disulfiram operates as an irreversible inhibitor of the enzyme aldehyde dehydrogenase (ALDH).

Under normal physiological conditions, ingested ethanol is metabolized in the liver by alcohol dehydrogenase (ADH) into acetaldehyde (a toxic, intermediate metabolite). Aldehyde dehydrogenase (ALDH) then rapidly converts acetaldehyde into harmless acetic acid (acetate), which breaks down into water and carbon dioxide. Disulfiram blocks this second metabolic step:

                 Alcohol Dehydrogenase (ADH)            Aldehyde Dehydrogenase (ALDH)
  [ ETHANOL ] ─────────────────────────────────► [ ACETALDEHYDE ] ─────────X─────────► [ ACETIC ACID ]
                                                        │              (BLOCKED BY
                                                        ▼              DISULFIRAM)
                                             TOXIC ACCUMULATION (5-10x)
                                            Severe Physical Distress:
                                            • Flushing & throbbing headache
                                            • Violent nausea & vomiting
                                            • Palpitations & tachycardia
                                            • Hypotension & chest tightness

The Disulfiram-Alcohol Reaction: If an individual ingests alcohol while taking disulfiram, blood acetaldehyde concentrations skyrocket to 5 to 10 times higher than normal levels. Within 10 to 30 minutes, the individual experiences severe, distressing physical symptoms:

• Intense cutaneous facial flushing and bloodshot eyes.
• Throbbing head and neck pain.
• Violent nausea, copious vomiting, and abdominal cramping.
• Tachycardia, palpitations, tachypnea, and diaphoresis.
• Hypotension, dizziness, weakness, and chest constriction.
• In severe cases (with large amounts of alcohol), the reaction can progress to cardiovascular collapse, cardiac arrhythmias, myocardial infarction, acute congestive heart failure, convulsions, or death.

Aversion Therapy and Cognitive Requirements: Disulfiram is a pure psychological deterrent (aversion therapy). It has zero effect on neurological cravings, does not normalize neurotransmitters, and does not relieve protracted withdrawal. Its therapeutic efficacy relies entirely on the individual's conscious fear of becoming violently ill.

---

3. Naltrexone for AUD (Oral Revia and Injectable Vivitrol)

Pharmacological Mechanism: In the context of alcohol consumption, drinking stimulates the release of endogenous beta-endorphins. These endorphins bind to mu-opioid receptors, which removes an inhibitory GABAergic brake on dopamine neurons in the VTA, causing a rewarding dopamine spike in the nucleus accumbens.

Naltrexone is a mu-opioid receptor antagonist. By occupying mu-opioid receptors, naltrexone breaks this neurochemical chain: when the individual drinks alcohol, the endorphins are blocked from binding, preventing the surge of dopamine. Alcohol is rendered unrewarding—the individual may still experience motor impairment, but the euphoric "buzz" is eliminated.

• Clinical Indications and Goals:
  • Naltrexone reduces overall alcohol cravings.
  • It significantly reduces the number of heavy drinking days and prevents a single "slip" or "lapse" from turning into a catastrophic, multi-week binge.
  • It is effective both for total abstinence and for harm-reduction goals (moderation or reduction of heavy drinking).
• The Sinclair Method (Targeted Dosing / Pharmacological Extinction): While FDA-approved for daily dosing in abstinent individuals, many addiction clinicians utilize the Sinclair Method. Under this protocol, individuals take oral naltrexone (50 mg) strictly one hour before their first drink of the day. Over months, drinking without the opioid-mediated endorphin reward leads to "pharmacological extinction," progressively eroding the conditioned brain response to alcohol cues.
• Formulations: Oral daily tablet (Revia, 50 mg) or monthly intramuscular injection (Vivitrol, 380 mg gluteal injection every 4 weeks). Vivitrol circumvents daily pill adherence challenges.

---

Comparative Summary: Medications for Alcohol and Tobacco Use Disorders

---

Off-Label Pharmacotherapies for Alcohol Use Disorder

When FDA-approved medications are poorly tolerated, contraindicated, or ineffective, evidence-based addiction guidelines support several off-label medications:

1. Gabapentin (Neurontin):
   • Mechanism: Modulates voltage-gated calcium channels containing the $\alpha_2\delta$ subunit, indirectly increasing GABA neurotransmission.
   • Clinical Role: Excellent for treating early protracted alcohol withdrawal, targeting insomnia, generalized anxiety, restlessness, and cravings. It is cleared renally (safe in mild-to-moderate liver disease). However, peer specialists must note that gabapentin possesses potential for misuse and sedation, especially if combined with opioids or sedatives.
2. Topiramate (Topamax):
   • Mechanism: Antagonizes AMPA/kainate glutamate receptors and potentiates $GABA_A$ neurotransmission.
   • Clinical Role: Demonstrates robust efficacy in reducing heavy drinking days, alcohol cravings, and impulsivity. Notable adverse effects include cognitive slowing (often colloquially referred to by patients as "Dopamax"), word-finding difficulty, paresthesias (tingling in fingers/toes), taste perversion (carbonated beverages taste flat), and weight loss.

---

Pharmacotherapies for Tobacco / Nicotine Use Disorder

Tobacco use disorder remains the single greatest cause of preventable death, cancer, cardiovascular disease, and chronic lung disease globally. In behavioral health and addiction recovery settings, smoking prevalence ranges from 60% to over 80%, and individuals in long-term substance recovery are statistically more likely to die from tobacco-related illnesses than from their primary drug of choice. First-line pharmacotherapies include:

┌────────────────────────────────────────────────────────────────────────────────────────┐
│                     TOBACCO / NICOTINE PHARMACOTHERAPY SPECTRUM                        │
├──────────────────────────┬─────────────────────────────┬───────────────────────────────┤
│ 1. Nicotine Replacement  │ 2. Bupropion SR (Zyban)     │ 3. Varenicline (Chantix)      │
│ • Delivers clean nicotine│ • Non-nicotine NDRI tablet  │ • Partial α4β2 agonist        │
│ • Transdermal patch      │ • Reduces cravings & weight │ • Blocks smoking reward       │
│ • Gum, lozenge, spray    │ • LOWERS SEIZURE THRESHOLD  │ • Most effective monotherapy  │
│ • Combination NRT best   │ • Contraindicated in eating │ • Take with water after meals │
│   (Patch + Gum/Lozenge)  │   disorders & acute detox   │   to prevent nausea           │
└──────────────────────────┴─────────────────────────────┴───────────────────────────────┘

1. Nicotine Replacement Therapy (NRT)

NRT provides "clean," controlled doses of nicotine to satisfy physical neurochemical dependence and alleviate acute withdrawal symptoms (irritability, anxiety, restlessness, weight gain, insomnia) without exposing the individual to the toxic carcinogens, carbon monoxide, and tar found in burning tobacco.

• The Five Delivery Modalities:
  • Transdermal Patch (Long-Acting): Provides steady, basal nicotine delivery over 16 or 24 hours. Available in step-down doses (e.g., 21 mg, 14 mg, 7 mg). Side effects include local skin irritation and vivid dreams (mitigated by removing the 24-hour patch at bedtime).
  • Nicotine Gum (Short-Acting): 2 mg and 4 mg strengths. Requires a specific "chew and park" technique: chew briefly until a peppery taste or tingling sensation emerges, then park the gum between the cheek and gum tissue for buccal mucosal absorption. Swallowing saliva rapidly without parking causes gastrointestinal upset, nausea, and hiccups.
  • Nicotine Lozenge (Short-Acting): Dissolves slowly in the mouth over 20-30 minutes. Do not bite, chew, or swallow whole.
  • Important Behavioral Rule for Oral NRT: Avoid eating or drinking acidic beverages (coffee, soda, orange juice, tea) for at least 15 minutes before and during gum or lozenge use, as acid significantly reduces oral mucosal nicotine absorption.
  • Nasal Spray and Oral Inhaler (Prescription): Nasal spray delivers rapid nicotine spikes mimicking cigarette kinetics; oral inhaler replicates hand-to-mouth behavioral rituals.
• Combination NRT (Gold Standard): Combining a long-acting formulation (transdermal patch for consistent baseline blood levels) with an acute, short-acting formulation (gum or lozenge for breakthrough cravings triggered by stress or environmental cues) produces dramatically higher long-term cessation rates than monotherapy.

2. Bupropion SR (Zyban / Wellbutrin SR)

• Mechanism: Norepinephrine-Dopamine Reuptake Inhibitor (NDRI). By mildly boosting synaptic dopamine and noradrenaline levels, it mimics the neurochemical reward of nicotine and diminishes withdrawal symptoms.
• Clinical Benefits: Non-nicotine oral tablet; assists in delaying or mitigating post-cessation weight gain; highly beneficial for individuals with co-occurring depressive symptoms.
• Critical Contraindications: Bupropion significantly lowers the seizure threshold. It is strictly contraindicated in individuals with:
  • A current or past history of seizure disorders.
  • A current or prior diagnosis of anorexia nervosa or bulimia.
  • Individuals undergoing acute withdrawal from alcohol or sedatives (benzodiazepines).

3. Varenicline (Chantix)

• Mechanism: A selective partial agonist at $\alpha_4\beta_2$ nicotinic acetylcholine receptors.
  • Dual Action: Its partial agonism stimulates moderate, steady dopamine release in the brain reward pathway, relieving nicotine withdrawal symptoms and cravings. Simultaneously, its high binding affinity blocks inhaled nicotine from attaching to the receptor; if the individual slips and smokes a cigarette, they receive zero pleasurable nicotine reinforcement.
• Efficacy: Clinically proven to be the most effective single monotherapy for smoking cessation, consistently outperforming bupropion and single-agent NRT in head-to-head randomized trials.
• Administration and Side Effects: Titrated over one week before the target quit date. The most common adverse effect is nausea (prevented by taking the tablet with a full meal and a large glass of water), along with insomnia and vivid dreams. Historical concerns regarding neuropsychiatric risks (depression, suicidal ideation) were evaluated in the large-scale EAGLES clinical trial, which found no significant increase in psychiatric events compared to placebo, leading the FDA to remove its former black-box warning.

---

The Peer Specialist Role in Alcohol and Tobacco Recovery

Peer specialists support individuals exploring MAUD and tobacco cessation through a compassionate, non-coercive lens:

• Dismantling Recovery Hierarchies: Many traditional recovery spaces treat tobacco as an acceptable, benign habit while treating alcohol medications with skepticism. Peer specialists normalize that recovery encompasses whole-person health and that treating tobacco dependence increases, rather than decreases, the likelihood of sustained sobriety from alcohol and illicit drugs.
• Exploring Readiness and Ambivalence: Using motivational interviewing to assess where the peer sits regarding alcohol reduction or smoking cessation without imposing unsolicited advice.
• Supporting Adherence and Refill Schedules: Assisting peers in managing high-frequency regimens (such as Acamprosate's TID schedule) and anticipating medication refills before holidays or weekends.